Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 2;11(3):574.
doi: 10.3390/vaccines11030574.

Is SARS-CoV-2 Vaccination of Subjects with a Prior History of Allergies Dangerous? Experiences in the Veneto Region of Italy

Silvia Cocchio  1 , Gloria Girolametto  1 , Alice Pierobon  2 , Patrizia Furlan  1 , Emanuela Destefani  2 , Lorenzo Bulegato  2 , Antonio Stano  2 , Silvia Fietta  2 , Annachiara Poletto  2 , Vincenzo Baldo  1
Affiliations

Is SARS-CoV-2 Vaccination of Subjects with a Prior History of Allergies Dangerous? Experiences in the Veneto Region of Italy

Silvia Cocchio et al. Vaccines (Basel). .

Abstract

Adverse events after SARS-CoV-2 vaccinations have caused alarm to some individuals with previously diagnosed allergies. The aim of this study was to investigate whether the risk of adverse reactions was actually higher in this subgroup. To this end, we carried out an observational descriptive analysis of vaccines administered in a "protected setting" in the Veneto region of Italy between December 2020 and December 2022. Reactions were classified using systemic organic classification (SOC), and their severity was assessed using the criteria of the Italian Drug Agency (AIFA). A total of 421 subjects were vaccinated with 1050 doses, 95.0% of which were administered without adverse events. In all, 53 subjects reported 87 SOC reactions (1.6 reactions/person), and 18.3% of these reactions were severe. One person was hospitalized, but all subjects enjoyed complete remission. Reporting rates were 9.0%, 3.1%, and 1.2% for first, second, and third doses, respectively. The most frequent reactions involved the respiratory system (2.3%), the cutaneous and subcutaneous systems (2.1%), and the nervous system (1.7%). Multivariate analyses (adjOR (95% CI)) revealed that the probability of experiencing at least one reaction significantly declined with increases in age [0.95 (0.94-0.97)] and in the number of doses received, i.e., 75% [0.25 (0.13-0.49)] for second doses and 88% [0.12 (0.04-0.39)] for third doses. These results indicated that vaccinations could be safely administered; few reactions were reported, and there were no permanent adverse outcomes.

Keywords: SARS-CoV-2; allergies; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distributions of subjects vaccinated, numbers of subjects reporting at least one post-vaccination adverse reaction, and numbers of post-vaccination adverse events reported.
Figure 2
Figure 2
Distribution percentages of post-vaccination reactions classified through SOC classification, for each number of doses administered.
See this image and copyright information in PMC

References

    1. Lurie N., Saville M., Hatchett R., Halton J. Developing COVID-19 Vaccines at Pandemic Speed. N. Engl. J. Med. 2020;382:1969–1973. doi: 10.1056/NEJMp2005630. - DOI - PubMed
    1. Baldo V., Reno C., Cocchio S., Fantini M.P. SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead. Vaccines. 2021;9:21. doi: 10.3390/vaccines9010021. - DOI - PMC - PubMed
    1. Rodríguez N.O., Berasategui M.A., Caballer B.D.L.H., Santiago A.V. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy. J. Investig. Allergol. Clin. Immunol. 2021;31:89–91. doi: 10.18176/jiaci.0665. - DOI - PubMed
    1. Temiz S.A., Abdelmaksoud A., Wollina U., Kutlu O., Dursun R., Patil A., Lotti T., Goldust M., Vestita M. Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review. J. Cosmet. Dermatol. 2022;21:4–12. doi: 10.1111/jocd.14613. - DOI - PMC - PubMed
    1. Shimabukuro T.T., Cole M., Su J.R. Reports of Anaphylaxis after Receipt of mRNA COVID-19 Vaccines in the US—14 December 2020–18 January 2021. JAMA. 2021;325:1101. doi: 10.1001/jama.2021.1967. - DOI - PMC - PubMed